Abstract
Here, we review a novel concept namely the compensatory immune-regulatory reflex system (CIRS) as applied to the pathophysiology of major depressive disorder (MDD) and bipolar disorder (BD). There is evidence that a substantial subset of individuals with MDD and BD exhibit an activation of the immune-inflammatory response system (IRS), as indicated by an increased production of macrophagic M1 and T helper (Th)-1 pro-inflammatory cytokines, interleukin (IL)-6 trans-signaling, positive acute phase proteins (APPs), and complement factors. These immune aberrations appear to be evident during the course of major affective episodes of either depressive or (hypo) manic polarity. Here, we review (a) the current state of the art of CIRS functions in both mood disorders and (b) the possible role of CIRS-related biomarkers for the understanding of affective disorders within the framework of precision psychiatry that could also provide novel drug targets for both MDD and BD. CIRS-related abnormalities in mood disorders include elevated Th-2 and T regulatory (Treg) activities with increased IL-4 and IL-10 production, classical IL-6 signaling, increased levels of sIL-1R antagonist (sIL-1RA), soluble IL-2 (sIL-2R) and tumor necrosis factor–α- receptors, and positive APPs, including haptoglobin, hemopexin, α1-acid glycoprotein, α1-antitrypsin, and ceruloplasmin. It is concluded that CIRS is involved in MDD and BD by regulating the primary immune-inflammatory response, thereby contributing to spontaneous and antidepressant-promoted recovery from the acute phase of illness. Signs of activated IRS and CIRS pathways are observed in the remitted phases of both disorders indicating that there is no return to the original homeostasis after an acute episode, while later episodes of mood disorders are characterized by sensitized IRS and CIRS responses. New z-unit weighted composite biomarker scores are proposed, which reflect different aspects of IRS versus CIRS activation and may be used to estimate different IRS/CIRS activity ratios in mood and other neuroimmune disorders.
Similar content being viewed by others
References
Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M (1984) Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 41(5):484–486
Irwin M, Gillin JC (1987) Impaired natural killer cell activity among depressed patients. Psychiatry Res 20(2):181–182
Roitt IM, Brostoff J, Male DK (1985) In: Immunology. Gower Medical Publishing, New York
Maes M, Bosmans E, Suy E, Minner B, Raus J (1989) Impaired lymphocyte stimulation by mitogens in severely depressed patients. A complex interface with HPA-axis hyperfunction, noradrenergic activity and the ageing process. Br J Psychiatry 155:793–798
Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J (1991) Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 84(4):379–386
Maes M, Lin A, Kenis G, Egyed B, Bosmans E (2000) The effects of noradrenaline and alpha-2 adrenoceptor agents on the production of monocytic products. Psychiatry Res 96(3):245–253
Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990) Immune disturbances during major depression: Upregulated expression of interleukin-2 receptors. Neuropsychobiology 24(3):115–120
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550
Spulber S, Bartfai T, Schultzberg M (2009) IL-1/IL-1ra balance in the brain revisited - evidence from transgenic mouse models. Brain Behav Immun 23(5):573–579
Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135(5):3172–3177
Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 113(8):619–627
Claman HN (1972) Corticosteroids and lymphoid cells. N Engl J Med 287(8):388–397
Ranelletti FO, Musiani P, Maggiano N, Lauriola L, Piantelli M (1983) Modulation of glucocorticoid inhibitory action on human lymphocyte mitogenesis: Dependence on mitogen concentration and T-cell maturity. Cell Immunol 76(1):22–28
Bloemena E, van Oers MH, Weinreich S, Yong SL, Schellekens PT (1988) Prednisolone and cyclosporin a exert differential inhibitory effects on T-cell proliferation in vitro. Clin Immunol Immunopathol 48(3):380–391
Maes M (1995) Evidence for an immune response in major depression: A review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry 19(1):11–38
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34(4):301–309
Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J Psychiatr Res 29(2):141–152
Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001) Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 11(3):203–208
Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 71(2):171–186
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5):446–457
Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J Affect Disord 139(3):230–239
Hiles SA, Baker AL, de Malmanche T, Attia J (2012) Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: A meta-analysis. Psychol Med 42(10):2015–2026
Valkanova V, Ebmeier KP, Allan CL (2013) CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies. J Affect Disord 150(3):736–744
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M (2015) Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49:206–215
Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, de Andrade NQ, Morris G, Fernandes BS, Brunoni AR, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF (2017) Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: Systematic review and meta-analysis. Mol Neurobiol. https://doi.org/10.1007/s12035-017-0632-1
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M et al (2017) Peripheral cytokine and chemokine alterations in depression: A meta-analysis of 82 studies. Acta Psychiatr Scand 135(5):373–387
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013) Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol Psychiatry 74(1):15–25
Munkholm K, Braüner JV, Kessing LV, Vinberg M (2013) Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J Psychiatr Res 47(9):1119–1133
Maes M, Berk M, Goehler L, Song C, Anderson G, Gałecki P, Leonard B (2012) Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10:66
Ward NS, Casserly B, Ayala A (2008) The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 29(4):617–625 viii
Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24(7):1125–1128
Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A (2003) Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 31(7):2068–2071
Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL et al (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 204(6):1463–1474
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174(5):1209–1220
Ayala A, Chaudry IH (1996) Immune dysfunction in murine polymicrobial sepsis: Mediators, macrophages, lymphocytes and apoptosis. Shock 6(Suppl 1):S27–S38
Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA (2012) Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 72(6):1491–1501
Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, Ungaro R, Davis R, Cuenca AG, Gentile LF, Nacionales DC et al (2014) Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg 76(1):21–29; discussion 29-30
Rosenthal MD, Moore FA (2015) Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. J Adv Nutr Hum Metab 1(1). e784.
Maes M, Vandewoude M, Scharpé S, De Clercq L, Stevens W, Lepoutre L, Schotte C (1991) Anthropometric and biochemical assessment of the nutritional state in depression: Evidence for lower visceral protein plasma levels in depression. J Affect Disord 23(1):25–33
Maes M, Scharpé S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy E (1992) Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: Further evidence for the existence of an inflammatory response during that illness. J Affect Disord 24(3):183–192
Maes M, Wauters A, Neels H, Scharpé S, Van Gastel A, D'Hondt P, Peeters D, Cosyns P et al (1995) Total serum protein and serum protein fractions in depression: Relationships to depressive symptoms and glucocorticoid activity. J Affect Disord 34(1):61–69
Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep 6:13
Maes M, Song C, Yirmiya R (2012) Targeting IL-1 in depression. Expert Opin Ther Targets 16(11):1097–1112
Arend WP, Guthridge CJ (2000) Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 59(Suppl 1):i60–i64
Anisman H, Ravindran AV, Griffiths J, Merali Z (1999) Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry 46(12):1649–1655
Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Devane CL (2009) Pro-inflammatory biomakers in depression: Treatment with venlafaxine. World J Biol Psychiatry 10(4):313–323
Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV (2010) Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry 18(2):172–176
Corwin EJ, Johnston N, Pugh L (2008) Symptoms of postpartum depression associated with elevated levels of interleukin-1 beta during the first month postpartum. Biol Res Nurs 10(2):128–133
Maes M, Mihaylova I, Kubera M, Ringel K (2012) Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 36(1):169–175
Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R (1995) Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord 36(1–2):29–36
Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9(11):853–858
Sowa-Kućma M, Styczeń K, Siwek M, Misztak P, Nowak RJ, Dudek D, Rybakowski JK, Nowak G, Maes M (2017) Lipid peroxidation and immune biomarkers are associated with major depression and its phenotypes, including treatment-resistant depression and melancholia. Neurotox res. Nov 4. https://doi.org/10.1007/s12640-017-9835-5
Sowa-Kućma M, Styczeń K, Siwek M, Misztak P, Nowak RJ, Dudek D, Rybakowski JK, Nowak G et al (2018) Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. Prog Neuro-Psychopharmacol Biol Psychiatry 81:372–383
Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V (1999) Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40(4):171–176
Monfrim X, Gazal M, De Leon PB, Quevedo L, Souza LD, Jansen K, Oses JP, Pinheiro RT et al (2014) Immune dysfunction in bipolar disorder and suicide risk: Is there an association between peripheral corticotropin-releasing hormone and interleukin-1β? Bipolar Disord 16(7):741–747
Tsai SY, Chung KH, Huang SH, Chen PH, Lee HC, Kuo CJ (2014) Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission. Bipolar Disord 16(8):800–808
Pandey GN, Ren X, Rizavi HS, Zhang H (2015) Abnormal gene expression of proinflammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder. Bipolar Disord 17(6):636–644
Milaneschi Y, Corsi AM, Penninx BW, Bandinelli S, Guralnik JM, Ferrucci L (2009) Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: The InCHIANTI study. Biol Psychiatry 65(11):973–978
Idriss HT, Naismith JH (2000) TNF alpha and the TNF receptor superfamily: Structure-function relationship(s). Microsc Res Tech 50(3):184–195
Pfeffer K (2003) Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14(3–4):185–191
Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF (2007) The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48(4):751–762
Olmos G, Lladó J (2014) Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity. Mediat Inflamm 2014:861231
Bouma MG, Buurman WA (1999) Assay of soluble tumor necrosis factor receptors. In: Evans TJ (ed) Methods in Molecular Medicine, Vol 36: Septic Shock. Humana Press Inc., Totowa, pp. 91–100
Huang ZS, Chiang BL, Hsu KL (2000) Serum level of soluble tumor necrosis factor receptor II (sTNF-R75) is apparently an index of overall monocyte-related infectious and inflammatory activity. Am J Med Sci 320(3):183–187
Selinsky CL, Boroughs KL, Halsey WA Jr, Howell MD (1998) Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I. Immunology 94(1):88–93
Su X, Zhou T, Yang P, Edwards CK 3rd, Mountz JD (1998) Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum 41(1):139–149
Banks WA, Plotkin SR, Kastin AJ (1995) Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 2(3):161–165
Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P et al (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21(11):2883–2886
Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, Teixeira AL (2011) Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 261(2):139–143
O'Brien SM, Scully P, Scott LV, Dinan TG (2006) Cytokine profiles in bipolar affective disorder: Focus on acutely ill patients. J Affect Disord 90(2–3):263–267
Ortiz-Domínguez A, Hernández ME, Berlanga C, Gutiérrez-Mora D, Moreno J, Heinze G, Pavón L (2007) Immune variations in bipolar disorder: Phasic differences. Bipolar Disord 9(6):596–602
Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F (2009) Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 116(3):214–217
Siwek M, Sowa-Kućma M, Styczeń K, Misztak P, Nowak RJ, Szewczyk B, Dudek D, Rybakowski JK et al (2017) Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder. Mol Neurobiol 54(8):5883–5893
Caruso C, Candore G, Cigna D, Colucci AT, Modica MA (1993) Biological significance of soluble IL-2 receptor. Mediat Inflamm 2(1):3–21
Witkowska AM (2005) On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediat Inflamm 2005(3):121–130
Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12(3):180–190
Malek TR, Castro I (2010) Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33(2):153–165
Arenas-Ramirez N, Woytschak J, Boyman O (2015) Interleukin-2: Biology, design and application. Trends Immunol 36(12):763–777
Dummer R, Posseckert G, Nestle F, Witzgall R, Burger M, Becker JC, Schäfer E, Wiede J et al (1992) Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: Explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? J Invest Dermatol 98(1):50–54
Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ, Ansell SM (2011) Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118:2809–2820
Yang L, Ma QL, Yao W, Zhang Q, Chen HP, Wang GS, Wang CZ (2011) Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+ regulatory T cells in COPD. Respir Res 2:142
Vanmaris R, Rijkers GT (2017) Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 34:122–129
Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B et al (1992) Evidence for a systemic immune activation during depression: Results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22(1):45–53
Maes M, Stevens WJ, Declerck LS, Bridts CH, Peeters D, Schotte C, Cosyns P (1993) Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: Further evidence for an inflammatory process during that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 17(2):241–255
Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696–1709
Maes M, Bosmans E, Suy E, Vandervorst C, Dejonckheere C, Raus J (1991) Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients. J Affect Disord 21(2):133–140
Maes M, Bosmans E, Scharpé S, D'Hondt P, Desnyder R (1995) Plasma soluble interleukin-2-receptor in depression: Relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity. Eur Psychiatry 10(8):397–403
Maes M (1998) Interleukin-2 and schizophrenia. Psychiatry Res 77(1):63–64
Maes M, Anderson G, Kubera M, Berk M (2014) Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 18(5):495–512
Slyepchenko A, Maes M, Köhler CA, Anderson G, Quevedo J, Alves GS, Berk M, Fernandes BS et al (2016) T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. Neurosci Biobehav Rev 64:83–100
Maes M, Scharpé S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P (1993) Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49(1):11–27
Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K (1996) Indicators of immune activation in major depression. Psychiatry Res 64(3):161–167
Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, De Jongh R, Bosmans E (1999) Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 45(7):833–839
Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosmans E, Scharpe S et al (1989) The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 49(3):211–219
Woodward EA, Prêle CM, Nicholson SE, Kolesnik TB, Hart PH (2010) The anti-inflammatory effects of interleukin-4 are not mediated by suppressor of cytokine signalling-1 (SOCS1). Immunology 131(1):118–127
Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117(4):1162–1172
Adeegbe DO, Nishikawa H (2013) Natural and induced T regulatory cells in cancer. Front Immunol 4:190
Tran DQ (2012) TGF-β: The sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 4(1):29–37
Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8(7):523–532
Romagnani P, Annunziato F, Piccinni MP, Maggi E, Romagnani S (2000) Th1/Th2 cells, their associated molecules and role in pathophysiology. Eur Cytokine Netw 11(3):510–511
Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD (2010) Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol 87(6):1011–1018
Lawrence DA (1996) Transforming growth factor-beta: A general review. Eur Cytokine Netw 7(3):363–374
Chaudhury A, Howe PH (2009) The tale of transforming growth factor-beta (TGFbeta) signaling: A soigné enigma. IUBMB Life 61(10):929–939
Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765
Mosser DM, Zhang X (2008) Interleukin-10: New perspectives on an old cytokine. Immunol Rev 226:205–218
Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M et al (2001) Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 105(1–2):45–55
Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26(8):797–808
Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104(1–3):91–95
Fiedorowicz JG, Prossin AR, Johnson CP, Christensen GE, Magnotta VA, Wemmie JA (2015) Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord 187:172–178
Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant’Anna M et al (2011) Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: Differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 33(3):268–274
Wiener CD, Moreira FP, Cardoso TA, Mondin TC, da Silva Magalhães PV, Kapczinski F, de Mattos Souza LD, da Silva RA et al (2017) Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder. J Neuroimmunol 307:33–36
Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpé S (1999) Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20(4):370–379
Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (2001) Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 21(2):199–206
Grosse L, Hoogenboezem T, Ambrée O, Bellingrath S, Jörgens S, de Wit HJ, Wijkhuijs AM, Arolt V et al (2016) Deficiencies of the T and natural killer cell system in major depressive disorder: T regulatory cell defects are associated with inflammatory monocyte activation. Brain Behav Immun 54:38–44
Grosse L, Carvalho LA, Birkenhager TK, Hoogendijk WJ, Kushner SA, Drexhage HA, Bergink V (2016) Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology 233(9):1679–1688
Maes M (1993) A review on the acute phase response in major depression. Rev Neurosci 4(4):407–416
Oliviero S, Morrone G, Cortese R (1987) The human haptoglobin gene: Transcriptional regulation during development and acute phase induction. EMBO J 6(7):1905–1912
Arredouani MS, Kasran A, Vanoirbeek JA, Berger FG, Baumann H, Ceuppens JL (2005) Haptoglobin dampens endotoxin-induced inflammatory effects both in vitro and in vivo. Immunology 114(2):263–271
Yang H, Wang H, Levine YA, Gunasekaran MK, Wang Y, Addorisio M, Zhu S, Li W et al (2016) Identification of CD163 as an anti-inflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight 1(7):e85375
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5(4):331–342
Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, Tracey KJ, Warren HS (2012) Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol 189(4):2017–2022
Smith A, McCulloh RJ (2015) Hemopexin and haptoglobin: Allies against heme toxicity from hemoglobin not contenders. Front Physiol 6:187
Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94(1):119–126
Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D (1999) Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 145(2):287–292
Saeed SA, Ahmad N, Ahmed S (2007) Dual inhibition of cyclooxygenase and lipoxygenase by human haptoglobin: Its polymorphism and relation to hemoglobin binding. Biochem Biophys Res Commun 353(4):915–920
de Kleijn DP, Smeets MB, Kemmeren PP, Lim SK, Van Middelaar BJ, Velema E, Schoneveld A, Pasterkamp G et al (2002) Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J 16(9):1123–1125
Quaye IK (2008) Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 102(8):735–742
Maes M, Delanghe J, Scharpé S, Meltzer HY, Cosyns P, Suy E, Bosmans E (1994) Haptoglobin phenotypes and gene frequencies in unipolar major depression. Am J Psychiatry 151(1):112–116
Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP (2007) Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis 191(1):48–53
Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpé S (1997) Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res 66(1):1–11
Rolla S, Ingoglia G, Bardina V, Silengo L, Altruda F, Novelli F, Tolosano E (2013) Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development. J Immunol 191(11):5451–5459
Hochepied T, Berger FG, Baumann H, Libert C (2003) Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 14(1):25–34
Jonigk D, Al-Omari M, Maegel L, Müller M, Izykowski N, Hong J, Hong K, Kim SH et al (2013) Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A 110(37):15007–15012
Bergin DA, Hurley K, McElvaney NG, Reeves EP (2012) Alpha-1 antitrypsin: A potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp 60(2):81–97
Chapman AL, Mocatta TJ, Shiva S, Seidel A, Chen B, Khalilova I, Paumann-Page ME, Jameson GN et al (2013) Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem 288(9):6465–6477
Bakhautdin B, Febbraio M, Goksoy E, de la Motte CA, Gulen MF, Childers EP, Hazen SL, Li X et al (2013) Protective role of macrophage-derived ceruloplasmin in inflammatory bowel disease. Gut 62(2):209–219
Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764–785
Gomes C, Martinho FC, Barbosa DS, Antunes LS, Póvoa HCC, Baltus THL, Morelli NR, Vargas HO et al (2017) Increased root canal endotoxin levels are associated with chronic apical periodontitis, increased oxidative and Nitrosative stress, major depression, severity of depression, and a lowered quality of life. Mol Neurobiol. https://doi.org/10.1007/s12035-017-0545-z
Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011) The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):702–721
Roomruangwong C, Barbosa DS, de Farias CC, Matsumoto AK, Baltus THL, Morelli NR, Kanchanatawan B, Duleu S et al (2017) Natural regulatory IgM-mediated autoimmune responses directed against malondialdehyde regulate oxidative and nitrosative pathways and coupled with IgM responses to nitroso-adducts attenuate depressive and physiosomatic symptoms at the end of term pregnancy. Psychiatry Clin Neurosci. https://doi.org/10.1111/pcn.12625
Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: New pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418
Antelman SM, Levine J, Gershon S (2000) Time-dependent sensitization: The odyssey of a scientific heresy from the laboratory to the door of the clinic. Mol Psychiatry 5(4):350–356
Bell IR, Schwartz GE, Amend D, Peterson JM, Stini WA (1994) Sensitization to early life stress and response to chemical odors in older adults. Biol Psychiatry 35(11):857–863
Maes M, Ombelet W, De Jongh R, Kenis G, Bosmans E (2001) The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affect Disord 63(1–3):85–92
Maes M, Ringel K, Kubera M, Berk M, Rybakowski J (2012) Increased autoimmune activity against 5-HT: A key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 136(3):386–392
Celik C, Erdem M, Cayci T, Ozdemir B, Ozgur Akgul E, Kurt YG, Yaman H, Isintas M et al (2010) The association between serum levels of neopterin and number of depressive episodes of major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 34(2):372–375
Maes M, Meltzer HY, Stevens W, Calabrese J, Cosyns P (1994) Natural killer cell activity in major depression: Relation to circulating natural killer cells, cellular indices of the immune response, and depressive phenomenology. Prog Neuro-Psychopharmacol Biol Psychiatry 18(4):717–730
Xia Z, DePierre JW, Nässberger L (1996) Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34(1):27–37
Xia Z, Depierre JW, Nässberger L (1996) The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes. J Pharm Pharmacol 48(1):115–116
Qiu W, Wu M, Liu S, Chen B, Pan C, Yang M, Wang KJ (2017) Suppressive immunoregulatory effects of three antidepressants via inhibition of the nuclear factor-κB activation assessed using primary macrophages of carp (Cyprinus carpio). Toxicol Appl Pharmacol 322:1–8
Maes M (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):664–675
Kubera M, Basta-Kaim A, Wróbel A, Maes M, Dudek D (2004) Increased mitogen-induced lymphocyte proliferation in treatment resistant depression: A preliminary study. Neuro Endocrinol Lett 25(3):207–210
Kubera M, Van Bockstaele D, Maes M (1999) Leukocyte subsets in treatment-resistant major depression. Pol J Pharmacol 51(6):547–549
Morris G, Anderson G, Galecki P, Berk M, Maes M (2013) A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Med 11:64
Maes M, Song C, Lin A, DeJong R, Van Gastel A, Kenis G, Bosmans E, DeMeester I, Neels H, Janca A, Scharpe S, Smith RS (1998) Immune and clinical correlates of psychological stress-induced production of interferon-γ and interleukin-10 in humans. Cytokines, Stress and Immunity; Editors: Plotnikoff NP, Faith RE, Murgo AJ, Good RA, pp 39–50. https://doi.org/10.1201/9781420048193.ch3
Guimarães PM, Scavuzzi BM, Stadtlober NP, Franchi Santos LFDR, Lozovoy MAB, Iriyoda TMV, Costa NT, Reiche EMV et al (2017) Cytokines in systemic lupus erythematosus: Far beyond Th1/Th2 dualism lupus: Cytokine profiles. Immunol Cell Biol 95(9):824–831
Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, Hayley AC, Pasco JA et al (2014) Oxidative & nitrosative stress in depression: Why so much stress? Neurosci Biobehav Rev 45:46–62
Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):676–692
Liu T, Zhong S, Liao X, Chen J, He T, Lai S, Jia Y (2015) A meta-analysis of oxidative stress markers in depression. PLoS One 10(10):e0138904
Morris G, Walder K, Carvalho AF, Tye SJ, Lucas K, Berk M, Maes M (2018) The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases. Neurosci Biobehav Rev 84:453–469
Morris G, Berk M, Klein H, Walder K, Galecki P, Maes M (2017) Nitrosative stress, Hypernitrosylation, and autoimmune responses to Nitrosylated proteins: New pathways in Neuroprogressive disorders including depression and chronic fatigue syndrome. Mol Neurobiol 54(6):4271–4291
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maes, M., Carvalho, A.F. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. Mol Neurobiol 55, 8885–8903 (2018). https://doi.org/10.1007/s12035-018-1016-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-018-1016-x